menu
    • menu

    Company profile for H. Lundbeck AS

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lundbeck is a global pharmaceutical company highly committed to improving the quality of life for people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinso...
    Lundbeck is a global pharmaceutical company highly committed to improving the quality of life for people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases. More information about Lundbeck

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    H. Lundbeck ASDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    Ottiliavej 9 2500 Valby
    Telephone
    Telephone
    +45 3630 1311
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lundbeck.com/global
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 303

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 11518

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Lundbeck acquires all outstanding shares of Longboard Pharma
    Lundbeck acquires all outstanding shares of Longboard Pharma

    04 Dec 2024

    // PRESS RELEASE

    https://www.lundbeck.com/us/newsroom/2024/lundbeck-to-acquire-longboard-pharmaceuticals-in-a-strategic-deal

    PRESS RELEASE
    04 Dec 2024
    Share Share
    Lundbeck Initiates Phase III Trial with Amlenetug for MSA
    Lundbeck Initiates Phase III Trial with Amlenetug for MSA

    27 Nov 2024

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2024-11-27/lundbeck-initiates-a-phase-iii-trial-with-amlenetug-for-the-treatment-of-multiple-system-atrophy

    PHARMAWEB
    27 Nov 2024
    Share Share
    Lundbeck slashes value of $250M Abide buyout after pain setback
    Lundbeck slashes value of $250M Abide buyout after pain setback

    24 Oct 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/lundbeck-slashes-value-250m-abide-buyout-after-pain-setback

    FIERCE BIOTECH
    24 Oct 2024
    Share Share
    Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal
    Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal

    15 Oct 2024

    // REUTERS

    https://www.reuters.com/markets/deals/lundbeck-buy-longboard-pharma-26-billion-deal-2024-10-14/

    REUTERS
    15 Oct 2024
    Share Share
    Lundbeck taps Charles River for AI-enabled neuro drug discovery
    Lundbeck taps Charles River for AI-enabled neuro drug discovery

    02 Oct 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/lundbeck-taps-charles-river-ai-enabled-neuro-drug-discovery

    FIERCE BIOTECH
    02 Oct 2024
    Share Share
    Barbara Corcoran Raises Awareness For Alzheimer's
    Barbara Corcoran Raises Awareness For Alzheimer's

    26 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240926223627/en

    BUSINESSWIRE
    26 Sep 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Citalopram Hydrobromide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Citalopram Hydrobromide

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 12384

    Submission : 1997-02-24

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2010-222 - Rev 00

    Issue Date : 2017-01-27

    Type : Chemical

    Substance Number : 2288

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Diazoxide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Diazoxide

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2017-06-02

    Pay. Date : 2017-05-01

    DMF Number : 7031

    Submission : 1987-06-22

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 218MF10985

    Registrant's Address : Via Quarta Strada, 2 Padova Italy

    Initial Date of Registration : 2006-12-18

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 45562-1740

    Start Marketing Date : 2022-01-26

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (100kg/100kg)

    Marketing Category : DRUG FOR FURTHER PRO...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Escitalopram Oxalate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Escitalopram Oxalate

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 14103

    Submission : 1999-04-29

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 222MF10216

    Registrant's Address : Ottiliavej 9, DK-2500, Valby, Copenhagen, Denmark

    Initial Date of Registration : 2010-08-10

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 45562-1130

    Start Marketing Date : 2010-07-06

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : DRUG FOR FURTHER PRO...

    KDMF arrow-down
    ✖

    Registrant Name : Lundbeck Korea Ltd.

    Registration Date : 2021-03-22

    Registration Number : 20210322-209-J-902

    Manufacturer Name : H. Lundbeck A/S

    Manufacturer Address : Oddenvej 182, Lumsas 4500 Nykøbing Sjælland, Denmark

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Trimipramine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Trimipramine

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-05-23

    Pay. Date : 2013-02-21

    DMF Number : 5900

    Submission : 1985-04-22

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2011-329 - Rev 00

    Issue Date : 2018-01-24

    Type : Chemical

    Substance Number : 534

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 45562-1739

    Start Marketing Date : 2012-07-17

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : DRUG FOR FURTHER PRO...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Vortioxetine Hydrobromide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Vortioxetine Hydrobromide

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 21224

    Submission : 2008-01-17

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 230MF10076

    Registrant's Address : Via Quarta Strada, 2 Padova, Italy

    Initial Date of Registration : 2018-07-03

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 45562-1135

    Start Marketing Date : 2013-12-05

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : DRUG FOR FURTHER PRO...

    KDMF arrow-down
    ✖

    Registrant Name : Lundbeck Korea Ltd.

    Registration Date : 2014-07-24

    Registration Number : 4496-4-ND

    Manufacturer Name : Lundbeck Pharmaceuticals Italy SPA@[Microchem SRL, manufacturer of micronized process]

    Manufacturer Address : Viale dell\'Industria, 54 - 35129, Padova (PD), Italy @Fiorenzuola D\'Arda (PC) - Via Turati 2, Italy

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Argatroban

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Argatroban

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-10-05

    Pay. Date : 2013-09-26

    DMF Number : 21304

    Submission : 2008-01-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 45562-1124

    Start Marketing Date : 2005-12-14

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : DRUG FOR FURTHER PRO...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Dapsone

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Dapsone

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 15065

    Submission : 2000-09-29

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 45562-1120

    Start Marketing Date : 2001-03-09

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : DRUG FOR FURTHER PRO...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Desipramine Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Desipramine Hydrochloride

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-01-26

    Pay. Date : 2014-03-26

    DMF Number : 3374

    Submission : 1978-10-04

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 45562-1736

    Start Marketing Date : 2004-01-15

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : DRUG FOR FURTHER PRO...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Imipramine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Imipramine

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 22104

    Submission : 2008-10-15

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 45562-1127

    Start Marketing Date : 2008-11-25

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : DRUG FOR FURTHER PRO...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Metoclopramide Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Metoclopramide Hydrochloride

    Denmark

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-07-28

    Pay. Date : 2016-07-21

    DMF Number : 4877

    Submission : 1983-03-26

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 45562-1737

    Start Marketing Date : 1998-01-07

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : DRUG FOR FURTHER PRO...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Denmark's Lundbeck Bets on Epilepsy Drug with $2.6 Bln Longboard Deal

    Details:

    Lundbeck gains access to LP352 (bexicaserin), a novel 5-HT2C agonist in development for seizures associated with DEEs, including Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies.


    Lead Product(s): Bexicaserin

    Therapeutic Area: Neurology Brand Name: LP352

    Study Phase: Phase IIIProduct Type: Small molecule

    Recipient: Longboard Pharmaceuticals

    Deal Size: $2,600.0 million Upfront Cash: $2,600.0 million

    Deal Type: Acquisition October 14, 2024

    blank

    01

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bexicaserin

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Recipient : Longboard Pharmaceuticals

    Deal Size : $2,600.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Denmark's Lundbeck Bets on Epilepsy Drug with $2.6 Bln Longboard Deal

    Details : Lundbeck gains access to LP352 (bexicaserin), a novel 5-HT2C agonist in development for seizures associated with DEEs, including Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies.

    Brand Name : LP352

    Molecule Type : Small molecule

    Upfront Cash : $2,600.0 million

    October 14, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Charles River and Lundbeck Use AI To Discover Neurological Disease Drugs

    Details:

    The agreement aims to advance the discovery of novel drugs for neurological disease by utilizing Logica which translates biological insights into optimized preclinical candidates.


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Small molecule

    Recipient: Charles River Laboratories, Inc

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement October 02, 2024

    blank

    02

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Neurology

    Highest Development Status : Discovery Platform

    Recipient : Charles River Laboratories, Inc

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Charles River and Lundbeck Use AI To Discover Neurological Disease Drugs

    Details : The agreement aims to advance the discovery of novel drugs for neurological disease by utilizing Logica which translates biological insights into optimized preclinical candidates.

    Brand Name : Undisclosed

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lundbeck Partners with Takeda in the US, Opts for Royalties, Focuses on Rexulti

    Details:

    Lundbeck will cease all promotional efforts for Trintellix (vortioxetine hbr) with Takeda in the U.S. fully reallocate resources to other growth opportunities and accelerate growth for these products.


    Lead Product(s): Vortioxetine Hydrobromide

    Therapeutic Area: Psychiatry/Psychology Brand Name: Trintellix

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Takeda Pharmaceutical

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration August 01, 2024

    blank

    03

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vortioxetine Hydrobromide

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Takeda Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Lundbeck Partners with Takeda in the US, Opts for Royalties, Focuses on Rexulti

    Details : Lundbeck will cease all promotional efforts for Trintellix (vortioxetine hbr) with Takeda in the U.S. fully reallocate resources to other growth opportunities and accelerate growth for these products.

    Brand Name : Trintellix

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    August 01, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Otsuka and Lundbeck Announce FDA Acceptance for Brexpiprazole in PTSD Treatment

    Details:

    Rexulti (brexpiprazole) is an partial agonist of serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).


    Lead Product(s): Brexpiprazole,Sertraline Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti

    Study Phase: Phase IIIProduct Type: Small molecule

    Recipient: Otsuka Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 25, 2024

    blank

    04

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Recipient : Otsuka Pharmaceutical

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Otsuka and Lundbeck Announce FDA Acceptance for Brexpiprazole in PTSD Treatment

    Details : Rexulti (brexpiprazole) is an partial agonist of serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).

    Brand Name : Rexulti

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    June 25, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole

    Details:

    Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder.


    Lead Product(s): Brexpiprazole,Sertraline Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti

    Study Phase: Phase IIIProduct Type: Small molecule

    Recipient: Otsuka Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 09, 2024

    blank

    05

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Recipient : Otsuka Pharmaceutical

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole

    Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder.

    Brand Name : Rexulti

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 09, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole and Sertraline Combination

    Details:

    Rexulti (brexpiprazole) 5-HT2A receptor, is being evaluated in combination with sertraline in late-stage clinical trials with adult patients for the treatment of post-traumatic stress disorder.


    Lead Product(s): Brexpiprazole,Sertraline Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti

    Study Phase: Phase IIIProduct Type: Small molecule

    Recipient: Otsuka Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 09, 2024

    blank

    06

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Recipient : Otsuka Pharmaceutical

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole and Sertraline Combination

    Details : Rexulti (brexpiprazole) 5-HT2A receptor, is being evaluated in combination with sertraline in late-stage clinical trials with adult patients for the treatment of post-traumatic stress disorder.

    Brand Name : Rexulti

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 09, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Trea...

    Details:

    Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).


    Lead Product(s): Brexpiprazole,Sertraline Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti

    Study Phase: Phase IIIProduct Type: Small molecule

    Recipient: Otsuka Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 07, 2023

    blank

    07

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Recipient : Otsuka Pharmaceutical

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazo...

    Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).

    Brand Name : Rexulti

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 07, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) ...

    Details:

    Rexulti (brexpiprazole) is an atypical antipsychotic, is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s disease.


    Lead Product(s): Brexpiprazole

    Therapeutic Area: Psychiatry/Psychology Brand Name: Rexulti

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Otsuka Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 11, 2023

    blank

    08

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Brexpiprazole

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Recipient : Otsuka Pharmaceutical

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New ...

    Details : Rexulti (brexpiprazole) is an atypical antipsychotic, is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s disease.

    Brand Name : Rexulti

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 11, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck

    Details:

    Under the agreement, Neuro3 will receive a worldwide license for intellectual property covering two clinical stage and one pre-clinical stage KCNQ2 activator programs and will be responsible for their further development through clinical PoC for the treatment of epilepsy.


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Undisclosed

    Sponsor: Neuro3 Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement May 08, 2023

    blank

    09

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Neurology

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : Neuro3 Therapeutics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stag...

    Details : Under the agreement, Neuro3 will receive a worldwide license for intellectual property covering two clinical stage and one pre-clinical stage KCNQ2 activator programs and will be responsible for their further development through clinical PoC for the trea...

    Brand Name : Undisclosed

    Molecule Type : Undisclosed

    Upfront Cash : Undisclosed

    May 08, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment ...

    Details:

    Abilify (aripiprazole) action includes a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. It is approved by USFDA for the treatment of schizophrenia and for bipolar I disorder in adults.


    Lead Product(s): Aripiprazole

    Therapeutic Area: Psychiatry/Psychology Brand Name: Abilify Asimtufii

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Otsuka Holdings

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 28, 2023

    blank

    10

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    H. Lundbeck AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Aripiprazole

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Otsuka Holdings

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-...

    Details : Abilify (aripiprazole) action includes a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. It is approved by USFDA for the treatment of schizophrenia and for bipolar I disorder in adults.

    Brand Name : Abilify Asimtufii

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 28, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    FDA

    read-more
    read-more

    01

    FDA Audited

    USA
    Antibody Engineering
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Antibody Engineering
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2014-08-01

    H. Lundbeck AS

    City : Deerfield

    State : IL

    Country/Area : US

    Zip : 60015-2542

    District : CHI

    Center : CDER

    Project Area : Postmarket Surv. and Epidemiolog...

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2014-08-01

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    FDA Audited

    USA
    Antibody Engineering
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Antibody Engineering
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2009-05-08

    H. Lundbeck AS

    City : Valby

    State :

    Country/Area : DK

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2009-05-08

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    FDA Audited

    USA
    Antibody Engineering
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Antibody Engineering
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2013-06-10

    H. Lundbeck AS

    City : Valby

    State :

    Country/Area : DK

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2013-06-10

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    FDA Audited

    USA
    Antibody Engineering
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Antibody Engineering
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2013-06-17

    H. Lundbeck AS

    City : Nykobing Sj

    State :

    Country/Area : DK

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2013-06-17

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    FDA Audited

    USA
    Antibody Engineering
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Antibody Engineering
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2012-09-28

    H. Lundbeck AS

    City : Padova

    State :

    Country/Area : IT

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2012-09-28

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    FDA Audited

    USA
    Antibody Engineering
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Antibody Engineering
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2009-03-13

    H. Lundbeck AS

    City : Padova

    State :

    Country/Area : IT

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2009-03-13

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    07

    FDA Audited

    USA
    Antibody Engineering
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Antibody Engineering
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2015-04-17

    H. Lundbeck AS

    City : Padova

    State :

    Country/Area : IT

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2015-04-17

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    08

    FDA Audited

    USA
    Antibody Engineering
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Antibody Engineering
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2010-06-02

    H. Lundbeck AS

    City : Deerfield

    State : IL

    Country/Area : US

    Zip : 60015

    District : CHI

    Center : CDER

    Project Area : Postmarket Surv. and Epidemiolog...

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2010-06-02

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    09

    FDA Audited

    USA
    Antibody Engineering
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    Antibody Engineering
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2017-05-12

    H. Lundbeck AS

    City : Padova

    State :

    Country/Area : IT

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2017-05-12

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact H. Lundbeck AS and get a quotation

    H. Lundbeck AS is a supplier offers 33 products (APIs, Excipients or Intermediates).

    Find a price of Citalopram Hydrobromide bulk with DMF, CEP offered by H. Lundbeck AS

    Find a price of Diazoxide bulk with DMF, JDMF offered by H. Lundbeck AS

    Find a price of Escitalopram Oxalate bulk with DMF, JDMF offered by H. Lundbeck AS

    Find a price of Trimipramine bulk with DMF, CEP offered by H. Lundbeck AS

    Find a price of Vortioxetine Hydrobromide bulk with DMF, JDMF offered by H. Lundbeck AS

    Find a price of Argatroban bulk with DMF offered by H. Lundbeck AS

    Find a price of Argatroban Monohydrate bulk with JDMF offered by H. Lundbeck AS

    Find a price of Clomipramine Hydrochloride bulk with DMF offered by H. Lundbeck AS

    Find a price of Dapsone bulk with DMF offered by H. Lundbeck AS

    Find a price of Desipramine Hydrochloride bulk with DMF offered by H. Lundbeck AS

    Find a price of Imipramine bulk with DMF offered by H. Lundbeck AS

    Find a price of Indomethacin Sodium bulk with JDMF offered by H. Lundbeck AS

    Find a price of Metoclopramide Hydrochloride bulk with DMF offered by H. Lundbeck AS

    Find a price of Nalmefene Hydrochloride bulk with JDMF offered by H. Lundbeck AS

    Find a price of Ritodrine Hydrochloride bulk with JDMF offered by H. Lundbeck AS

    Find a price of Thip Hydrochloride bulk with DMF offered by H. Lundbeck AS

    Find a price of Vortioxetine Hydrobromide bulk with JDMF offered by H. Lundbeck AS

    Find a price of Alfuzosin HCl bulk offered by H. Lundbeck AS

    Find a price of Calcium Amphomycin bulk offered by H. Lundbeck AS

    Find a price of Ethotoin bulk offered by H. Lundbeck AS

    Find a price of Imipramine Hydrochloride bulk offered by H. Lundbeck AS

    Find a price of Melperone bulk offered by H. Lundbeck AS

    Find a price of Sertindole bulk offered by H. Lundbeck AS

    Find a price of Tedatioxetine Hydrobromide bulk offered by H. Lundbeck AS

    Find a price of Tetrabenazine bulk offered by H. Lundbeck AS

    Find a price of LU 3-010 bulk offered by H. Lundbeck AS

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN LAMSAS, DENMARK bulk offered by H. Lundbeck AS

    Find a price of LU-25-109-M DRUG SUBSTANCE bulk offered by H. Lundbeck AS

    Find a price of LU 28-179-CAPSULES bulk offered by H. Lundbeck AS

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND GENERAL OPERATING PROCEDURES IN SEAL SANDS, UNITED KINGDOM bulk offered by H. Lundbeck AS

    Find a price of FACILITY IN NYKOBING SJ., DENMARK bulk offered by H. Lundbeck AS

    Find a price of LU 28-179-C, DRUG SUBSTANCE bulk offered by H. Lundbeck AS

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND GENERAL OPERATING PROCEDURES IN VALBY, DENMARK bulk offered by H. Lundbeck AS

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search